Skip to main content
. Author manuscript; available in PMC: 2017 Jun 1.
Published in final edited form as: Psychoneuroendocrinology. 2016 Feb 26;68:156–162. doi: 10.1016/j.psyneuen.2016.02.025

Fig. 2.

Fig. 2

Vasopressin 1a receptor binding in the presence and absence of a selective receptor antagonist. (A) Incubation with the radioligand [125I]-phenylacetyl-D-Tyr(Me)-Phe-Gln-Asn-Arg-Pro-Arg-Tyr-NH2. (B) Co-incubation with radioligand and an excess of unlabeled selective vasopressin 1a receptor ligand d(CH2)51[Tyr(Me)2,Arg8]vasopressin in an adjacent section from the same brain. Exposure time was optimized to keep lateral septum binding within the linear range of iodinated standards; in this range non-specific binding was almost undetectable.